{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Biomarker-Driven Cancer Care Is Not Reaching All Americans

Activity Steps

Purpose of Activity

To explore the current inequity in cancer care surrounding a paradigm shift toward tissue- agnostic treatment based on tumor biology.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Describe the emerging targeted therapies of precision medicine available for cancer treatment.
  2. Analyze the reimbursement and practice gap barriers hindering access to cancer biomarker testing.
  3. Identify ways to narrow the access gap and ensure the equitable delivery of precision medicine to all Americans.
Price: $12.95


  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.

Test Code: OT0920
Published: September 2020
Expires: 9/2/2022
Sources: Oncology Times
Required Passing Score: 7/10 (70%)
Authors: Peggy Eastman
Topics: Biomarker